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Description:
Sickle cell anemia is a hematologic disorder impacting over 15 million people worldwide. It is
caused by a single point mutation in the gene hemoglobin-Betha, where a glu group is replaced
by val (GAG --- GTG) in the seventh codon (glu7val) of chromosome 1.While healthy
hemoglobin (HbA) carries oxygen through the blood, mutated hemoglobin (HbS) does the same
action, but it also goes through polymerization, a chemical process of linking monomers together
to form polymer chains. Polymerization is one of the key components that causes HbS cells to be
more likely to stick together in clusters when they are in close proximity, thus blocking the blood
flow in the human body. Researchers from prior studies have discovered that natural mutations
reduce polymerization and the sickling properties of the HbS molecules by blocking the
secondary interactions which impacts the stability of the HbS structure. In this study we are
comparing the antisickling properties of drugs in varied conditions in order to create a drug that
is effective in a O2-independent manner and with a 1:1 stoichiometry for lower dosage purposes.
.
We compared the main drugs and their respective structures being GBT-440 and VZHE-039.
Voxelotor is the first aromatic aldehyde with antisickling compounds that target the
polymerization of Hbs. VZHE-039 binds to Hb in a 2:1 ratio whereas GBT-440 binds with a 1:1
ratio. The drugs are in an R2 conformation and interact in the same binding site of the
hemoglobin. The major amino acids it interacts with are: The binding site of the protein are Val
1, Val 73, Asp 75, Met 76, Pro 77, Asn 78, Ser 131, Thr 134. GBT-440 and VZHE-039 are both
aldehydes that inhibit polymerization and antisickling and vary based on the presence of oxygen.
VZHE-39 is effective in both environments with 2.5% oxygen and no oxygen.
This study involves combining the oxygen-independent property of VZHE-039 (yellow) and the
1:1 ratio of GBT-440 (blue) to create a new drug (green) that acts in low and high oxygen
environments, with low doses. The specific structures responsible for the distinct actions of
VZHE-039 and GBT-440 are shown in the following figures as well as combined in the new
drug.

Figure 1: Demonstrates the structure of GBT-440 circling the
pyridine and pyrasol structures.

Figure 2: Structure of VZHE-039 and circled methyl hydroxy
moite in the pyrimidine ring.

Figure 3: VZHE-039 (yellow) and GBT-440 (blue) represented
after both PDB structures were superimposed and only the
Hemoglobin S proteins were removed.

Figure 4: New drug structure that consists of the structure of
GBT-440 and an addition of methyl hydroxy moite in the
pyrimidine ring.

Figure 5: Shows the predicted binding pose of the new drug
(green).

